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Receptor oligomerizationBesides some pharmacological, biochemical and biophysical evidences support the contention that
muscarinic acetylcholine receptors can form homo- and heterodimers, the existence of speciﬁc M3 and M5
muscarinic receptors oligomers in living cells is a new concept. Interestingly, this phenomenon might have
relevance in lymphocytic cholinergic function since both T- and B-cells naturally express high levels of these
two receptor subtypes. Here, by means of co-immunoprecipitation and bioluminescence resonance energy
transfer methods we demonstrated that M3 and M5 muscarinic receptors could form constitutive homo- and
heterodimers in transiently transfected HEK-293T cells. Interestingly, this receptor–receptor interaction was
unaltered by carbachol treatment but it was affected by the expression of a peptide corresponding to a
portion of the third intracellular loop of the M5 muscarinic receptor. In addition, the same peptide was able
to abrogate the carbachol-induced mitogen-activated protein kinase phosphorylation and the carbachol-
enhanced PHA-induced IL-2 production in derived lymphocytic T cells. Overall, these results suggest that the
third intracellular loop of the M5 muscarinic receptor might play a regulatory role in receptor function and
heteromerization, thus providing the molecular framework for a potential cholinergic-based therapeutic
intervention of the immune system.pt. de Patologia i Terapèutica
e), Pavelló de Govern, Av. Feixa
, Spain. Tel.: +34 934024280,
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Over the last decade G protein-coupled receptors (GPCRs) have
been shown to form constitutive homo- or heteromers, probably as
part of larger oligomeric protein structures [1]. The rationale of these
GPCR oligomeric complexes starts to be revealed and it opens new
perspectives for potential novel drug design. Indeed, GPCR oligomer-
ization leads to adaptations in receptor function and pharmacology,
for instance the receptor maturation, ligand binding, activation,
signaling, desensitization, endocytosis and trafﬁcking might be
somehow manoeuvred by these multiprotein structures [2]. In 1993
Maggio et al. offered strong indications for the existence of GPCR
dimers with the transcomplementation experiments between the M3
muscarinic acetylcholine receptor (mAChR) and the α2-adrenergic
receptor (α2AR) [3]. Brieﬂy, when a α2AR/M3 mAChR chimeras
consisting of ﬁve transmembrane (TM) regions of one receptor and
two of the other was expressed, there was a lack of ligand binding andof function that was recovered after co-expression of the two types of
chimeras. These results provide not only pharmacological evidence
that mAChR can form dimers but also that intermolecular protein–
protein interactions between two inactive receptor forms could result
in a dimeric complex with restored functional properties [3,4].
Subsequently, several studies showed that mAChRs, as many other
GPCRs, may also be arranged in oligomeric structures [5,6]. Certainly,
complex binding curves of mAChRs expressed in rabbit heart and rat
brain stem, together with computer assisted simulations of agonist
binding to M2 mAChR (M2R) expressed in cultured cells were
consistent with the contention of dimeric receptor-containing
putative M2R binding sites [7,8]. Also, binding studies using puriﬁed
porcine mAChRs ﬁt well with cooperative interactions phenomena
occurring within a receptor that is at least tetravalent and presumably
an oligomer [9]. Finally, by means of site-directed mutagenesis and
co-immunoprecipitation experiments of epitope-tagged M3R it was
demonstrated that these receptors form disulﬁde-linked as well as
non-covalent dimers/multimers [10,11]. Besides all these, biochem-
ical approaches clearly demonstrated a receptor–receptor interaction
they might have some disadvantages since in the course of these
experiments the cellular structure is destroyed by detergent treat-
ment. More recently, in order to assess whether mAChRs form
oligomers in living cells, a biophysical approach was performed, thus
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occurrence of constitutive homo- and hetero-oligomers among M1,
M2, and M3 mAChRs has been demonstrated in cultured cells [12,13].
On the other hand, there are enough evidences that point out to
the existence of a non-neuronal cholinergic system [14,15]. Indeed, by
means of several experimental approaches it has been demonstrated
that most of the cholinergic components which are expressed in
neurons (e.g. acetylcholine, choline acetyltransferase, high afﬁnity
choline transporter, muscarinic and nicotinic acetylcholine receptors
and acetylcholinesterase) are also present in lymphocytic cells, thus
constituting an independent cholinergic system that can be regulated
in an autocrine fashion [16]. Interestingly, stimulation of T and B cells
with muscarinic receptor agonists elicits intracellular calcium signal-
ing, up-regulates of c-Fos expression, and increases nitric oxide
synthesis and cytokine production [15,17]. Furthermore, it has been
demonstrated that a wide array of different mAChR subtypes are
expressed in lymphocytic cells. Therefore, immunohistochemical,
Western-blot and RT-PCR studies showed that the M3, M4 and M5
mAChRs are highly expressed and thus potentially involved in the
cholinergic-based immune cell function [15]. Certainly, it has been
shown that several mAChRs agonists affect the immune functions in
different modes, for instance while the treatment of isolated human
peripheral blood lymphocytes with oxotremorine, a non-selective
mAChR agonist, produced an enhancement of the IL-2 production and
cell proliferation, the injection of BALB/c mice with arecoline, a M1R,
M2R and M3R partial agonist, had the opposite effect [18,19]. Also,
treatment of human peripheral blood mononuclear cells with
pilocarpine, another non-selective mAChR agonist, decreased the
number of IL-2 receptor bearing cells with no modiﬁcation of the IL-2
production [20]. On the other hand, studies using a M1R/M5R KO
mouse indicated that these receptor subtypes are involved in the
regulation of cytokine (e.g., IL-6) production, which in turns leads to
the modulation of antibody class switching from IgM to IgG1, but are
not involved in the initial generation of the antibody response [21].
Finally, it has been demonstrated that immunological stimulation of
T- and B-lymphocytes, respectively, with T-cell activator phytohe-
magglutinin and B-cell activator Staphylococcus aureus Cowan I
upregulated M5RmRNA expression in cell line models of lymphocytes
[22]. Overall, all the accumulated evidences indicate that M3R and
M5R are co-expressed in the same lymphocytic cells where they play a
key role in the non-neuronal cholinergic system. However, it is
intriguing why a named cell (e.g. T-lymphocyte) co-expresses two
receptors, M3R and M5R, which have apparently similar functionality
after acetylcholine activation. In the present study we assessed the
ability of M3R andM5R to form homo- and heterodimers in living cells
by means of a combination of biochemical and biophysical
approaches. Interestingly, our results demonstrated that the M5R
third intracellular loop constitutes a molecular determinant in the
modulation of these receptor oligomers. Finally, this M5R third
intracellular loop was also shown to play a critical role in the
muscarinic cholinergic-mediated function in a T-lymphocytic cell
model, thus providing indication that this M5R domain is also
involved in the oligomeric receptor function.
2. Materials and methods
2.1. Materials
Dulbecco's modiﬁed Eagle's medium, penicillin/streptomycin and
fetal bovine serum were purchased from Invitrogen (Carlsbad, CA,
USA). N-[3H]-methylscopolamine ([3H]-NMS, 81 Ci/mmol) was from
Amersham Biosciences (Piscataway, NJ, USA). Restriction enzymes
were from New England Biolabs (Beverly, MA, USA) and h-
coelenterazine was obtained from Promega (Madison, WI, USA). The
rabbit anti-hemagglutinin (HA) polyclonal antibody (clone HA.11)
was purchased from Covance (Berkeley, CA, USA). Carbamylcholinechloride (carbachol), atropine sulfate and all other reagents were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
2.2. Plasmids constructs
The constructs presented herein were made using standard
molecular biology techniques employing PCR and fragment replace-
ment strategies. The cDNAs for the humanM3 andM5mAChRs (kindly
provided by T. Bonner, NIH, USA and D. Bello, ETH, Switzerland,
respectively) were subcloned into the mammalian expression vector
pcDNA-3.1 (Invitrogen) containing three HA epitopes (gift from P.
Calvo, SFU, CA, USA), thus resulting in the 3xHA-M3R-pcDNA3.1 and
3xHA-M5R-pcDNA3.1 vectors. Brieﬂy, 1.9- and 1.7-kb fragments
encoding the human M3R and M5R were respectively ampliﬁed
using sense and antisense primers harboring unique EcoRV and XbaI
sites and then subcloned into EcoRV/XbaI sites of the mammalian
pcDNA3.1-3xHA vector.
The cDNAs encoding the full-length M5R third intracellular loop
(from Thr210 to Ala450; M5R-3IL210–450), a fragment of the M5R third
intracellular loop (from Ser235 to Val409; M5R-3IL235–409) and the third
intracellular loop of the bovine rhodopsin (from His211 to Ala260; Ops-
3IL211–260), were subcloned into the InterPlay® mammalian TAP
system, pNTAP-B vector (Stratagene, La Jolla, CA, USA) resulting in the
pTAP-M5R-3IL210–450, pTAP-M5R-3IL235–409 and pTAP-Ops-3IL211–260
vectors, respectively. These constructs contain a streptavidin binding
peptide (SBP) tag and calmodulin binding peptide (CBP) tag at the N
terminus. Brieﬂy, the fragments of M5R were ampliﬁed from the
3xHA-M5R-pcDNA vector using sense and antisense primers harbor-
ing unique BamHI and EcoRI sites and the Expand High Fidelity PCR
System (Roche, Basel, Switzerland) and subcloned into BamHI/EcoRI
sites of the pNTAP-B vector. In a similar way, the 3IL of bovine
rhodopsin was ampliﬁed from the Rho-pMT4 vector (kindly provided
by Dr. H.G. Khorana, Massachusetts Institute of Technology, USA)
using sense and antisense primers harboring unique BamHI and EcoRI
sites and the Expand High Fidelity PCR System (Roche) and subcloned
into BamHI/EcoRI sites of the pNTAP-B vector.
M3RRluc and M5RRluc were constructed by ligating the Renilla
luciferase (Rluc) to the C-terminal tail of each receptor subtype.
Human M3 and M5 mAChRs coding sequences without their stop
codons were ampliﬁed from 3xHA-M3R-pcDNA and 3xHA-M5R-
pcDNA vectors using sense and antisense primers harboring unique
XhoI and EcoRI sites. The fragmentswere then subcloned in-frame into
humanized pRluc-N2 vectors (PerkinElmer, Waltham, MA, USA). In a
similar manner, M3RGFP2 and M5RGFP2 were constructed using sense
and antisense primers harbouring unique EcoRI and BamHI sites and
subcloned into the pGFP2-N1 vector (PerkinElmer). The reading frame
and PCR integrity of all cloned constructs were conﬁrmed by DNA
sequencing.
2.3. Cell culture and transfection
HEK-293T cells were maintained in Dulbecco's modiﬁed Eagle's
medium supplemented with 10% fetal calf serum (FCS), 100 U/ml
streptomycin, 100 µg/ml penicillin, 2 mM L-glutamine (all from
Invitrogen) at 37 °C in a humidiﬁed 5% CO2 incubator. For transfec-
tions, 2×106 cells were seeded into 100-mm dishes. About 24 h later,
cells were transfected with 4 µg of plasmid DNA/dish by using the
LipofectamineTM Plus reagent (Invitrogen) according to the manufac-
turer's instructions. For BRET assays, HEK-293T cells were transfected
using PolyEthylenImine reagent (PEI, Sigma-Aldrich) as described
previously [23].
Human acute T lymphoblastic leukaemia cells (Molt-3 cells,
European Collection of Cell Cultures (ECACC), London, UK) were
cultured in RPMI 1640 medium supplemented with 10% FCS, 2 mM
GlutaMAX-1, 1 mM sodium pyruvate, 100 U/ml streptomycin,
100 µg/ml penicillin at 37 °C in a humidiﬁed 10% CO2 environment.
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described previously [24].2.4. Membrane preparation and radioligand binding assay
About 48 h after transfection, HEK-293T cells were washed twice
with cold PBS, harvested and homogenized in binding buffer (25 mM
HEPES, pH 7.4, 5 mM MgCl2, 1 mM EDTA), using a Polytron tissue
homogenizer. Cell membranes were collected by centrifugation at
20,000 ×g for 15 min and homogenized as above. After centrifugation
at 40,000 ×g for 20 min at 4 °C, the ﬁnal pellet was resuspended in
binding buffer, and membranes were either used immediately or
frozen in liquid nitrogen and stored at−80 °C until required. Protein
concentration was determined by using the Bradford protein assay kit
(Bio-Rad, Hercules, CA, USA). In order to determine the afﬁnity of NMS
for each sample, membranes were incubated with different concen-
trations of [3H]-NMS (ranging from 12.5 pM to 1.5 nM) in 5 mM
sodium phosphate (pH 7.4) containing 5 mM MgCl2 at 25 °C for
60 min. The incubations were stopped by ﬁltration throughWhatman
(Maidstone, Kent, UK) GF/B ﬁlters and washed extensively with ice-
cold PBS prior to scintillation counting. Non-speciﬁc binding was
determined in the presence of 10 µM atropine.2.5. Inositol phosphate determination
Transfected HEK-293 cells were labeled for 18–24 h with [3H]-
myo-inositol (Amersham Biosciences) in DMEM containing glucose
and without inositol (Invitrogen). After labeling, cells were washed
and preincubated for 5 min in PBS at 37 °C, and subsequently
incubated in FCS free medium with different concentrations of
carbachol—or without carbachol—in the presence of 10 mM LiCl for
5 min. Reactions were stopped by perchloric acid addition. Inositol
phosphates (IPs) were extracted and separated on Dowex AG1-X8
columns (Bio-Rad). Total labeled IPs were then counted by liquid
scintillation.2.6. [35S]-GTPγS binding assay
HEK-293 cell membranes were diluted in an ice-cold buffer
containing 10 mM HEPES and 0.1 mM EDTA, 5 mM deoxycholate
(pH 7.4). Then theywere pelleted and resuspended in a binding buffer
consisting of 10 mMHEPES, 10 mMMgCl2, and 100 mMNaCl (pH 7.4)
at a ﬁnal protein concentration of 125 µg protein/ml. Incubations
were conducted in a ﬁnal assay volume of 1 ml (125 µg total protein)
for 1 h at 30 °C in the presence of 1 µM GDP and 0.3 nM [35S]-GTPγS
(Amersham Biosciences) and the suitable ligand concentration
(carbachol from 1 nM to 1 mM). The reaction was stopped by addition
of 5 ml of ice-cold buffer consisting in 10 mM HEPES (pH 7.4) and
1 mM MgCl2, immediately followed by rapid ﬁltration through glass
ﬁbre ﬁlters GF/C ﬁlters (Whatman) presoaked in the same buffer. The
ﬁlters were washed twice with 5 ml of ice-cold buffer and the
radioactivity was measured by scintillation counting. Nonspeciﬁc
binding was determined in the presence of 10 µMGTPγS. Assays were
performed in triplicate.2.7. Gel electrophoresis and immunoblotting
SDS/PAGE was performed using 6.5%, 10% or 15% polyacrylamide
gels. Proteins were transferred to PVDF membranes using a semi-dry
transfer system and immunoblotted with the indicated antibody and
then HRP-conjugated goat anti-rabbit IgG, HRP-conjugated rabbit
anti-mouse IgG. The immunoreactive bands were developed using a
chemiluminescent detection kit (Pierce, Rockford, IL, USA) [25].2.8. Immunoprecipitation and immunostaining
For immunoprecipitation, membranes from transiently trans-
fected HEK-293 or Molt-3 cells were solubilized in ice-cold radio
immuno precipitation assay (RIPA) buffer (50 mM Tris–HCl pH 7.4,
100 mM NaCl, 1% Triton-X100, 0.5% sodium deoxycholate, 0.2% SDS
and 1 mM EDTA) for 30 min on ice. The solubilized preparation was
then centrifuged at 16,100×g for 30 min. The supernatant (1 mg/ml)
was processed for immunoprecipitation, each step of which was
conducted with constant rotation at 0–4 °C. The supernatant was
incubated overnight with the indicated antibody. Then 40 µl of a
suspension of protein G cross linked to agarose beads was added and
the mixture was incubated overnight. Subsequently, the beads were
washed twice with ice-cold RIPA buffer, twice with ice cold RIPA
buffer diluted 1:10 in TBS (50 mM Tris–HCl, pH 7.4, 100 mM NaCl)
and once with TBS and aspirated to dryness with a 28-gauge needle.
Then, 100 µl of sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) sample buffer (0.125 M Tris–HCl pH 6.8, 4% SDS,
20% glycerol, 0.004% bromphenol blue) was added to each sample.
Immune complexes were dissociated by adding fresh dithiothreitol
(DTT) (50 mM ﬁnal concentration) and heating to 100 °C for 10 min.
Proteins were resolved and detected as described above.
For immunocytochemistry, Molt-3 cells (endogenously expressing
M3R and M5R) or transiently transfected HEK-293T cells were grown
on poly-D-lysine-coated glass coverslips and ﬁxed with 4% formalde-
hyde solution for 20 min followed by twowashes with PBS containing
20 mM glycine (buffer A) to quench the aldehyde groups. Then, after
permeabilizationwith buffer A containing 0.2% Triton X-100 for 5 min,
cells were treated with PBS containing 1% bovine serum albumin
(buffer B). After 1 h at room temperature, cells were labeled with the
indicated primary antibody for 1 h, extensively washed, and stained
with the indicated ﬂuorescently labeled secondary antibody. Samples
were rinsed and visualized on a Leica DMRB ﬂuorescence microscope
or a Leica SP1/MP confocal microscope. The primary antibodies used
were as follows: goat anti-M3R antibody (1:1000, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), rabbit anti-M5R antibody
(1:500, Santa Cruz Biotechnology) and mouse anti-SBP monoclonal
antibody (1/1000; kindly provided by the CMU-Universite de Geneve,
Switzerland). The secondary antibodies used were as follows: donkey
anti-goat-Cy2TM (1/200; Jackson ImmunoResearch Laboratories, Inc.,
West Grove, PA, USA), donkey anti-rabbit-Cy3TM (1/200; Jackson
ImmunoResearch Laboratories, Inc.), donkey anti-mouse Alexa Fluor-
488 and (1/2000; Molecular Probes, Eugene, OR, USA) and donkey
anti-rabbit Alexa Fluor-568 (1/2000; Molecular Probes).
2.9. BRET assay
Forty-eight hours after transfection of HEK-293T cells with a
constant (2 µg) of M3RRluc or M5RRluc and increasing amounts of
M3RGFP2 or M5RGFP2 (0.5–10 µg) were rapidly washed twice in PBS,
detached, and resuspended in the same buffer. Cell suspensions
(20 µg protein) were distributed in duplicate into 96-well black
microplates with a transparent bottom (Corning 3651, Corning
Incorporated, Corning, NY, USA) for ﬂuorescence measurement or
white plates withwhite bottom (Corning 3600, Corning Incorporated)
for BRET determination. The total ﬂuorescence of cell suspensions was
quantiﬁed and then divided by the background (mock-transfected
cells) in a FLUOstart Optima (BMG Labtechnologies, Offenburg,
Germany) equipped with a high-energy xenon ﬂash lamp, using a
10-nm bandwidth excitation ﬁlter at 400 nm (393–403 nm), and
10 nm bandwidth emission ﬁlters corresponding to 510 nm (506–
515 nm). Total bioluminescence was determined on samples incu-
bated 10 min with 5 µM h-coelenterazine using a Mithras LB 940
(Berthold Technologies, DLReady, Germany) as previously described
[25,26]. The background values for total luminescence were negligi-
ble, and they were subtracted from sample values.
Table 1
Ligand binding properties and PLC activation of M3R and M5R constructs.
Receptor
construct
[3H]-NMS Binding IP accumulation
KD (pM) Bmax (fmol/mg) EC50 (µM)
3xHA-M3R 63.2±20.8 529.1±42.5 7.2±0.8
3xHA-M3RRluc 58.3±19.2 483.0±39.3 5.3±0.2
3xHA-M3RGFP2 60.6±21.4 513.1±41.6 7.8±0.4
3xHA-M5R 86.2±16.5 520.2±27.8 1.5±0.2
3xHA-M5RRluc 92.1±15.3 541.5±32.7 2.6±0.8
3xHA-M5RGFP2 89.9±22.7 557.8±37.5 1.1±0.2
Radioligand binding studies on HEK-293T cell membranes expressing wild type, Rluc
and GFP2-tagged mAChRs were carried out as described under “Materials and
methods”. Curves were better ﬁtted by non-linear regression analysis assuming a
single binding site. KD values were determined by using GraphPad Prism software.
Results represent means±S.E. (n=4).
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in duplicate in 96-well white opaque microplates and incubated for
10 min at 25 °C in the absence or presence of carbachol. DeepBlueC
substrate (Molecular Probes) was added at a ﬁnal concentration of
5 µM, and readings were performed immediately after using the
Mithras LB 940 plate-reader that allows the sequential integration of
the signals detected with two ﬁlter settings [485 nm (440–500 nm)
and 530 nm (510–590 nm)]. The BRET ratio is deﬁned as: [(GFP2
emission at 500–530)/(Rluc emission 440–500)]−cf., where cf.
corresponds to (emission at 510–590)/(emission at 440–500) for
the receptor-Rluc construct expressed alone in the same experiment.
Luminescence and ﬂuorescence levels of GPCRs fusion proteins
have been found to be linearly correlated with receptor numbers [27].
Since this correlation is an intrinsic characteristic of each speciﬁc
receptor fusion protein, correlation curves have to be established for
each receptor construct. Thus, HEK 293 cells were transiently
transfected with increasing amounts of cDNA of of M3RRluc or
M5RRluc and M3RGFP2 or M5RGFP2 fusion protein constructs. Maximal
luminescence and ﬂuorescence was determined as described above
and correlated with the relative receptor number determined in the
same cell extracts as described in the “Membrane preparation and
radioligand binding assay” section. Luminescence and ﬂuorescence
were both plotted against binding sites, and linear regression curves
were generated. The standard curves generated for each single
experiment were used to transform ﬂuorescence and luminescence
values into femtomoles of receptor. Thus, the ﬂuorescence/lumines-
cence ratios were transformed into (receptor-YFP)/(receptor-Rluc)
ratios, which allowed us to determine accurate BRETmax and BRET50
values. To control the number of cells and also to express receptor
numbers in fmol/mg of total cell protein, the concentration of protein
was determined using a Bradford assay kit (Bio-Rad).
2.10. ERK phosphorylation
Molt-3 cells endogenously expressing the M3R and the M5R were
transiently transfected with the minigene encoding the M5R-3IL235–409
peptide, grown to 80% conﬂuence and rendered quiescent by serum
starvation overnight prior to ERK phosphorylation. Subsequently, an
additional 2 h pre-incubation in fresh serum-free medium was
performed to minimize basal activity before cells were challenged
with the muscarinic agonist carbachol for the time and concentration
indicated.Next, a rapid rinsingwith ice-cold PBSwasperformed inorder
toﬁnish stimulation and before the cellswere lysedwith 500 µl ice-cold
lysis buffer (50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1% Triton X-100,
protease andphosphatase inhibitor cocktail) during10 min. The cellular
debriswas removedby centrifugation at 13,000 ×g for 5 min at4 °C, and
the total protein content was measured using BCA Protein Assay
Reagent (Pierce). Aliquots corresponding to 5 µg of protein weremixed
with SDS-PAGE sample buffer, applied to 12% SDS-polyacrylamide gel
electrophoresis (SDS-PAGE) and analyzed by immunoblot. Extracellular
signal regulated kinase 1/2 (ERK1/2) activation was assayed by
incubating PVDF blots with a mouse anti-phospho-ERK1/2 antibody
(Sigma-Aldrich). Control blotswere also run inparallel, andprobedwith
rabbit anti-ERK1/2 antibody (Sigma-Aldrich) that recognized both
phosphorylated and unphosphorylated forms.
2.11. IL-2 production
The amount of IL-2 produced by Molt-3 cells (transfected with the
M5R-3IL235–409 minigene or mock pcDNA3.1) was determined using
and ELISA kit for human IL-2 (DuPont-New England Nuclear-
PerkinElmer). In brief, cell-free culture supernatants were obtained
by centrifugation at 500 ×g for 5 min. Sampleswere assayed following
manufacture's instruction and analyzed on an automated ELISA plate
reader. Data is expressed as IU (1 IU/ml=0.2 ng/ml of IL-2).2.12. Data analysis
All binding data and BRET saturation curves were analyzed using
the commercial program GraphPad PRISM 4.0 (GraphPad Prism, San
Diego, CA, USA). Isotherms were ﬁtted using a non-linear regression
equation assuming a single binding site, which provided BRETmax and
BRET50 values. The correlation between ﬂuorescence or luminescence
and receptor density was analyzed by a linear regression curve ﬁtting
with the same software. For statistical evaluation of the biochemical
data, unless otherwise speciﬁed, one-way analysis of variance
(ANOVA) was used. Group differences after signiﬁcant ANOVAs
were measured by post hoc Bonferroni's Multiple Comparison test.
3. Results
3.1. Expression of M3R and M5R muscarinic acetylcholine receptor fusion
proteins in living cells
The fusion proteins 3xHA-M3RRluc, 3xHA-M3RGFP2, 3xHA-M5RRluc
and 3xHA-M5RGFP2 together with the 3xHA-M3R and 3xHA-M5R were
transiently transfected into HEK-293T cells and radioligand binding
experiments were performed. As shown in Table 1 all receptor
constructs displayed similar afﬁnities for the receptor-speciﬁc
antagonist NMS, thus suggesting that the attachment of either GFP2
or Rluc to the C-terminal tail of the receptor do not alter the mAChR
ligand binding ability. Interestingly, the expression levels (Bmax) of
the different receptor constructs tested ranged between 400 and
600 fmol/mg of protein, thus being within the expected physiological
range [18,28]. Next, to validate the functionality of these fusion
proteins we tested the ability of these mAChRs constructs to couple to
the Gq/PLC pathway by measuring their capability to mediate
carbachol stimulated-IP accumulation. Thus, in HEK-293 cells tran-
siently transfected with the M3R and M5R constructs described above
the incubation with increasing concentrations of carbachol produced
a similar dose-dependent accumulation of inositol phosphate in all
the constructs tested (Fig. 1A). Interestingly, the EC50 values observed
with the different tagged mAChRs constructs were within the same
order of potency for each receptor subtype (Table 1). Overall, these
results indicated that the introduction of either Rluc or GFP2 proteins
to the M3R or M5R C-terminal tail do not alter neither the efﬁcacy nor
the potency of these receptor constructs to activate PLC.
Finally, we performed immunocytochemistry experiments and
confocal microscopy analysis to determine the subcellular distribution
of both M3R and M5R when expressed alone and in combination.
Under these conditions, permeabilized HEK-293 cells expressing both
M3R and M5R showed an overlapped distribution of these two
proteins (Fig. 1B). It is important to mention that M3R or M5R when
expressed alone did not show differences in their subcellular
distribution when compared to the doubly transfected cells
(Fig. 1B). Also, when cells were singly transfected with one receptor
Fig. 1. M3R/M5R interaction in HEK-293T cells. (A) Activation of PLC by M3R and M5R constructs. HEK-293 cells transiently transfected with the cDNAs encoding 3xHA-M3R (□),
3xHA-M3RGFP2 ( ), 3xHA-M3RRluc ( ) (M3R constructs) or 3xHA-M5R (□), 3xHA-M5RGFP2 ( ), 3xHA-M5RRluc ( ) (M5R constructs) were labeled overnight with myo-[3H]inositol
and the total inositol phosphate accumulation was determined after incubation of the cells with increasing concentrations of carbachol (CCH) (see Materials and methods). The
speciﬁc agonist-induced inositol phosphate increase is expressed as percentage over the basal level (agonist-untreated cells) for each transfection and normalized using themaximal
activation in the 3xHA-M3R and 3xHA-M5R transfected cells, respectively. Basal levels observed with the various receptor constructs were not signiﬁcantly different. Values are
means±S.E.M. of triplicate determinations of three independent experiments. (B) Immunoﬂuorescence localization of 3xHA-M3R and 3xHA-M5R in HEK-293T cells. Cells were
transiently cotransfected with the cDNAs encoding 3xHA-M3R, 3xHA-M5R or 3xHA-M3R plus 3xHA-M5R and processed for immunocytochemistry (seeMaterials andmethods) using
a goat anti-M3R and a rabbit anti-M5R. The bound primary antibodies were detected using donkey–anti-goat-Cy2 and donkey–anti-rabbit-Cy3. Superimposition of images reveals
receptor codistribution in yellow (merge). Scale bar: 10 µm.
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thus demonstrating that there was not cross reactivity between the
antibodies used and thus corroborating their speciﬁcity (Fig. 1B).
3.2. Oligomerization of M3R and M5R muscarinic acetylcholine receptors
Determination of protein–protein interactions in general, and
receptor–receptor interactions in particular, constitute an important
step in the study of a large number of cellular mechanisms. In
traditional protocols these interactions are ﬁrst conﬁrmed by means
of immobilized protein–protein interaction assays, such as co-
immunoprecipitation experiments. Consequently, we carried out co-
immunoprecipitation assays in HEK-293T cells transiently expressing
3xHA-tagged M5R, wild type M3R or both constructs. Thus, fromextracts of HEK-293T cells transiently transfected with HA-M5R and
M3R the rabbit anti-HA antibody co-immunoprecipitated a band of
75 kDa, which corresponds to the M3R (Fig. 2, lane 2, middle panel).
This band did not appear in immunoprecipitates from cells only
transfected with the cDNA for either HA-M5R or M3R (Fig. 1C, lanes 1
and 3, middle panel). Conversely, in extracts from these cells, the anti-
M3R antibody co-immunoprecipitated a band of 68 kDa
corresponding to the HA-M5R (Fig. 2).
Next, M3R–M5R heteromerization was tested by means of BRET
assays. Consequently, we examined the possibility of direct receptor–
receptor interaction by assessing quantitative BRET saturation curves
in HEK-293T co-transfected with a constant amount of M3RRluc and
increasing concentrations of the M5RGFP2. To this end, we ﬁrst
established a correlation between receptor numbers (determined by
Fig. 2. Co-immunoprecipitation of M3R andM5R in transiently transfected HEK-293T cells.
Cellswere transiently transfectedwith 3xHA-M5R (lane 1), 3xHA-M5RplusM3R (lane2) or
M3R (lane3),washed, solubilizedandprocessed for immunoprecipitationusing rabbit anti-
HA antibody (2 µg/ml; IP: HA) or goat anti-M3R (2 µg/ml; IP: HA). Solubilizedmembranes
(Crude) and immunoprecipitates (IP) were analyzed by SDS-PAGE and immunoblotted
using goat anti-M3R (1/1000) and rabbit anti-HA (1/2000) and horseradish-peroxidase
(HRP)-conjugated rabbit anti-goat or goat anti-rabbit as a secondary antibody. The
immunoreactive bands were visualized by chemiluminescence. These blots are represen-
tative of four different experiments with similar qualitative results.
Fig. 3. BRET-based study of M3R/M5R heterodimerization in HEK-293T cells. (A) BRET
saturation experiments between M3RRluc and M5RGFP2 were performed in the absence
(▄) or presence (○) of 10 µM carbachol. (B) BRET saturation experiments between
M3RRluc and M5RGFP2 were performed in the absence (▄) or presence of the minigenes
Ops-3IL211–260 (○) or M5R-3IL235–409 ( ). Both ﬂuorescence and luminescence of each
sample were determined as described in Materials and methods and transformed into
receptor number (see Supplementary material) prior to every experiment. We conﬁrm
equal expression of Rluc construct while monitoring the increase of GFP2 expression.
BRET ratio values were plotted as a function of the [M5RGFP2]/[M3RRluc]. The curves
represent nine saturation curves that were ﬁtted using a non-linear regression equation
assuming a single binding site.
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cence/ﬂuorescence intensity for each receptor-construct used (see
Supplementary material). Total luminescence and total ﬂuorescence
emitted by the Rluc and GFP2 receptor fusion proteins were measured
following the addition of the Rluc substrate h-coelenterazine and
direct excitation of the GFP2 at 400 nm, respectively. As expected, a
linear correlation between the receptor number and either the
luminescence or ﬂuorescence emitted by each receptor fusion protein
was obtained. Interestingly, the slopes for the two receptors tested
were similar (Supplementary material, Figs. 1 and 2). Finally, the
linear regression equations derived from “Supplementary material”
were thus used to transform the luminescence and ﬂuorescence
values into receptor number. Thus, BRET signals were plotted as a
function of the ratio between the receptorGFP2/receptorRluc numbers.
By using this quantitative BRET approach, where the expression
level of both the donor and acceptor protein in co-transfected cells is
known, a positive and saturable BRET signal for the transfer of energy
between the homodimeric muscarinic acetylcholine receptor pairs
M3RRluc/M3RGFP2 and M5RRluc/M5RGFP2 was observed (Supplementary
material, Figs. 1C and 2C) in agreementwith previous ﬁndings [13,29].
Interestingly, a positive and saturable BRET signal for the transfer of
energy between M3RRluc and M5RGFP2 was also obtained in HEK-293T
cells co-transfected with a constant amount of the M3RRluc (400 fmol/
mg of protein, monitored by luciferase activity) and increasing
concentrations of M5RGFP2 (from 130 to 1205 fmol/mg of protein,
monitored by ﬂuorescence intensity) (Fig. 3A). As the co-expression
of M3RRluc with soluble GFP2 protein led to marginal signals that
increased linearly with an increasing amount of GFP2 added (data not
shown), the hyperbolic BRET signal found for the M3RRluc/M5RGFP2pair argues for the selectivity of the interaction between M3R and
M5R, and also suggest that the distance between donor (M3RRluc) and
acceptor (M5RGFP2) is ≤10 nm.
Interestingly, when the BRET saturation curves were compared it
is noticeable that the concentration of acceptor giving 50% of the
maximum energy transfer (BRET50) for the M3R/M3R and M5R/M5R
homodimers were quite similar (1.59±0.29 and 1.76±0.32, respec-
tively) and within the same range to that observed for the
heterodimer M3R/M5R (1.58±0.27). These results suggest that M3R
andM5R have similar avidity to form both homo- and heterodimers in
living cells, thus the ability to form these oligomeric complexes will be
therefore determined by the relative M3R/M5R stoichiometry. Finally,
it is important to mention here that stimulation with the agonist
carbachol (10 µM) had neither effect on the BRET50 nor in the BRET
values, thus indicating that homo- and heterodimers are formed
constitutively and that receptor activation does not affect their
oligomerization state (Fig. 3A). These results are in agreement with
previously described studies showing that GPCR challenge failed to
promote BRET changes [30,31].
3.3. Structural determinants involved in M3R/M5R heterodimerization
The molecular mechanism driving mAChRs oligomerization has
been poorly elucidated. For instance, several reports have suggested
the participation of transmembrane helices and intracellular loops in
the oligomerization process [6]. Consequently, one of the proposed
structural determinants potentially involved in M3R/M5R oligomer-
ization is the large third intracellular loop. Therefore, in order to
investigate whether the M5R third intracellular loop play a role in
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contain the complete or partial sequence of theM5R third intracellular
loop (Fig. 4A). Brieﬂy, we constructed a ﬁrst minigene (3IL235–409)
encoding a fragment of the M5R third intracellular (Ser235–Val409),
and a secondminigene (3IL210–450) encoding the full-lengthM5R third
intracellular loop (Thr210–Ala450) (Fig. 4A). The rationale to make
these constructs is because the N-terminal part of the mAChRs 3IL is
known to be critical for coupling and activation of G proteins and we
wanted to discern if these M5R-3IL minigenes, by targeting the
receptor-G protein boundary, might compete for the G proteins. To
this end, experiments of agonist-induced stimulation of [35S]-GTPγS
binding to membranes from HEK-293 cells transfected with M5R in
the absence or presence of these minigenes were performed. Brieﬂy,
the co-expression of the M5R with the M5R-3IL210–450 resulted in a
signiﬁcant decrement in both the maximal response (Emax) and
potency (pEC50) (∼45% and 2.2 fold, respectively) of the carbachol-
mediated [35S]-GTPγS bindingwhen compared to the cells transfected
with M5R alone (Fig 4B). Interestingly, the expression of the M5R-
3IL235–409, which do not contain the putative G protein binding
epitope (Fig. 4A), did not have effect neither in the Emax nor in the
pEC50 of the M5R-mediated [35S]-GTPγS binding after carbachol
stimulation of (Fig. 4B). Overall, these results suggest that the
expression of the M5R-3IL210–450 inhibits the Gq/11 protein-coupled
mAChRs-mediated [35S]-GTPγS binding. Consequently, in order to
investigate whether the M5R third intracellular loop plays any role in
receptor oligomerization which is independent of G protein-binding
we choose to use the M5R-3IL235–409 minigene in our BRET experi-
ments committed to study the M3R/M5R heterodimerization. Inter-
estingly, previous studies suggested that peptides matching regions
potentially involved in receptor oligomerization might induce proto-
mer dissociation or dimer conformational rearrangements. These
changes can be followed by monitoring differences in BRET signals of
properly tagged receptors [32,33]. Consequently, to test whether
M5R-3IL235–409 peptide had any effect on M3R/M5R heterodimeriza-
tion we performed quantitative BRET saturation experiments co-
expressing a constant amount of the M3RRluc (380 fmol/mg of
protein) and increasing concentrations of M5RGFP2 (from 125 to
1110 fmol/mg of protein) in the absence and presence of the M5R-
3IL235–409 minigene construct. Interestingly, under these experimen-
tal conditions the expression of M5R-3IL235–409 peptide promoted a
30% reduction in the BRETmax, with no signiﬁcant change in the BRET50
(1.78±0.33), of the corresponding M3R/M5R heteromer–BRET satura-
tion curve (Fig. 3B). As the expression of the control peptide Ops-
3IL211–260 did not affect the BRETmax of the energy transfer between
M3RRluc and M5RGFP2 (a similar hyperbolic curve was observed), the
speciﬁcity of the M5R-3IL235–409-mediated BRETmax reduction could be
established (Fig. 3B). Overall, these results strongly indicate that the
third intracellular loop of the M5 mAChR (Ser235–Val409) might affect
the conformational framework of the heterodimer in a mode that is
independent of the receptor G protein-binding.
3.4. The M5R-3IL
235–409 speciﬁcally targets the M3R/M5R-mediated
function
To test whether the third intracellular loop of the M5R play any
speciﬁc role in the cholinergic function mediated by the M3R, the M5R
or the M3R/M5R heterodimer we tested the functionality of these
receptor combinations by monitoring the extent of phosphorylation
of extracellular signal-regulated kinases (ERK1/2) in response to
carbachol. First, we express the M5R-3IL235–409 in HEK-293T. Thus,
from extracts of HEK-293T cells transiently transfected with the
minigene encoding the M5R-3IL235–409 the mouse anti-SBP monoclo-
nal antibody detected a band of ∼28 kDa that matches the expected
size for the M5R-3IL235–409 cloned in pNTAP (Fig. 5A, lane 2, left
panel). Also, we checked the subcellular distribution of the M5R-
3IL235–409 by means of immunocytochemistry experiments andconfocal microscopy analysis. Under these conditions, permeabilized
HEK-293T cells expressing this construct showed clear cytosolic
distribution M5R-3IL235–409 (Fig. 5A, right panel). Interestingly, when
the M5R-3IL235–409 was coexpressed together with M3R and M5R a
partial overlapped distribution of M5R-3IL235–409 and M5R was
observed in discrete areas (Fig. 4B). Not big differences were observed
when the M5R-3IL235–409 was coexpressed with M5R alone (data not
shown). Thus, our results show that the M5R-3IL235–409 when
transfected in cells is heavily synthesized and that it might have
some degree of co-distribution with the mAChRs.
Next, to asses the functional consequences of the M5R-3IL235–409
expression in the mAChRs signaling we analyzed the functionality of
these receptors expressed in HEK-293T cells by monitoring the
phosphorylation of ERK1/2 after carbachol challenge. As expected, a
carbachol-mediated phosphorylation of ERK1/2 was observed in
HEK-293T cells transiently transfected with M3R, M4R, M5R and M3R/
M5R (Fig. 6A). Interestingly, overnight incubation with pertussis toxin
(PTX) signiﬁcantly reduced the M4R-mediated ERK1/2 phosphoryla-
tion but not the one mediated by the M3R, the M5R and the M3R/M5R
(Fig. 6A and B). These results indicate that while the M4R signals
mostly though a Gαi/o protein the M3R and the M5R signaling is
mediated by a PTX-resistant G protein. Subsequently, under these
experimental conditions we analyzed the effect of the M5R-3IL235–409
expression in M3R, M4R, M5R and M3R/M5R functionality. In HEK-
293T cells transiently expressing the M3R, M4R, M5R and M3R/M5R
the co-transfection of the Ops-3IL211–260 control peptide did not alter
the carbachol-mediated phosphorylation of ERK1/2 when compared
to the untransfected cells (data not shown). In addition, the co-
expression of M5R-3IL235–409 with M3R, M4R and M5R did not
signiﬁcantly affect the carbachol-mediated phosphorylation of
ERK1/2 as it was similar to that observed in the presence of the
control peptide (Fig. 7A and B). Interestingly, in HEK-293T cells
transiently cotransfected with M3R and M5R the coexpression of the
M5R-3IL235–409 abolished the carbachol-mediated ERK1/2 phosphor-
ylation (Fig. 7A and B). Overall, these results suggest that the third
intracellular loop of the M5R speciﬁcally regulate the M3R/M5R
heterodimer-mediated ERK1/2 phosphorylation, thus this is the ﬁrst
time that a speciﬁc function related to the M3R/M5R heterodimer is
described.
3.5. Expression and function of muscarinic acetylcholine receptors in
Molt-3 cells
A number of behavioral studies in lymphocytic cells have
previously demonstrated functional interactions between muscarinic
receptors [15,18,19]; however the mechanism(s) underlying these
are not clearly understood. Given the fact that both M3 and M5
mAChRs are highly coexpressed in many lymphocytic cells [15], these
constitute a good model to study the molecular and functional
interaction between M3R and M5R. For instance, we used Molt-3 cells,
a human leukemic T-cell line, as a T-lymphocyte cholinergic model
[34,35].
First, by using immunocytochemistry and confocal microscopy
analysis we analyzed the subcellular distribution of the endogenously
expressedM3R andM5R in Molt-3 cells. As for HEK-293T cells in Molt-
3 cells an overlapped distribution ofM3 andM5mAChRswas observed
(Fig. 8A). Next, to asses the physiological relevance of the interaction
between M3R and M5R co-immunoprecipitation experiments were
performed using Molt-3 cells extracts. Thus, from extracts of Molt-3
cells the rabbit anti-M3R antibody co-immunoprecipitated a band of
75 kDa, which corresponds to the M3R (Fig. 8B, lane 2). Interestingly,
the anti-M5R antibody was able to co-immunoprecipitate the M3R
(Fig. 8B, lane 3). These bands did not appear when an irrelevant rabbit
IgG was used for immunoprecipitation (Fig. 8B, lane 1), showing that
the reaction was speciﬁc. These results suggest that in Molt-3 cells
M3R and M5R might assemble into stable protein–protein complexes
Fig. 4. Schematic representation of the M5R. (A) Serpentine two-dimensional representation of the M5R sequence. The amino acids corresponding to the M5R-3IL235–409 peptide are depicted in ﬁlled circles. The asterisk denotes the putative
amino acids involved in G protein-binding (KAAxxL). In the bottom the amino acidic sequence of theM5R-3IL210–450 peptide is shown. The amino acids corresponding to the M5R-3IL235–409 peptide are underlined and the putative amino acids
involved in G protein-coupling arewithin the gray box. Also, the peptide corresponding to the third intracellular loop of the bovine rhodopsin (Ops-3IL211–260), used as a negative control, is shown. (B) Effect of M5R-3IL minigene expression on
the agonist-stimulated [35S]-GTPγS binding. HEK-293 T cells were transiently transfected with the cDNA (5 µg) encoding the M5R (■) or co-transfected with the M5R (5 µg) plus the minigene (5 µg) encoding the M5R-3IL235–409 (●) or the
M5R-3IL210–450 (▲) peptides. Binding of [35S]-GTPγS (0.3 nM) tomembranes from these cells wasmeasured after incubation with increasing concentrations of carbachol for 1 h at 30 °C in the absence. Values are expressed as percentage (%) of
speciﬁc binding to the sample in the absence of ligand (control). Data aremeans±S.D. from a representative experiment preformed in triplicate. To conﬁrm the transiently transfection of theminigenes total RNAwas isolated and subjected to
RT-PCR with speciﬁc primers (data not shown). On the right a schematic cartoon of the M5R structure parallel to the plasma membrane is shown. The schematic diagram was prepared by computational modeling using the rhodopsin as a

















Fig. 5. Expression of M5R-3IL235–409 in HEK-293T cells. (A) Cells were mock transfected (lane 1) or transfected with pTAP-M5R-3IL235–409 vector (5 µg cDNA; lane 2), washed,
solubilized and processed for immunoblotting. Solubilized material (20 µg/ml) was analyzed by SDS-PAGE and immunoblotted using a mouse anti-SBP monoclonal antibody and
horseradish-peroxidase (HRP)-conjugated goat anti-mouse as a secondary antibody. The immunoreactive bands were visualized by chemiluminescence. These blots are
representative of three different experiments with similar qualitative results. In the right panel an immunoﬂuorescence localization of M5R-3IL235–409 in HEK-293T cells is shown.
Cells were transiently transfected as before and processed for immunocytochemistry (see Materials and methods) using a mouse anti-SBP monoclonal antibody. The bound primary
antibody was detected using a donkey anti-mouse Alexa Fluor-488. Scale bar: 10 µm. (B) Immunoﬂuorescence localization of M5R-3IL235–409 and 3xHA-M5R in HEK-293T cells. Cells
were transiently cotransfected with the cDNAs encoding M5R-3IL235–409, 3xHA-M3R and 3xHA-M5R and processed for immunocytochemistry (see Materials and methods) using a
mouse anti-SBP monoclonal antibody and a rabbit anti-M5R polyclonal antibody. The bound primary antibodies were detected using donkey anti-mouse Alexa Fluor-488 and donkey
anti-rabbit Alexa Fluor-568. Superimposition of images reveals receptor codistribution in yellow (merge). Scale bar: 10 µm.
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immunoprecipitation, therefore making reasonable the idea that
these oligomeric complexes might have physiological relevance in
vivo. Finally, we tested the functionality of these endogenously
expressed receptors by monitoring the extent of phosphorylation ofFig. 6. mAChRs-mediated activation of ERK1/2 in HEK-293T cells. (A) Cells were transientl
preincubated with vehicle (−PTX) or with 100 ng/ml of pertussis toxin (+PTX) and then
determined by immunoblotting (see Materials and methods). Images are representative o
intensities of the immunoreactive bands on X-ray ﬁlm corresponding to ERK1/2 and
phosphorylated ERK1/2 were normalized using ERK1/2 and expressed as means±S.E.M. (ERK1/2 in response to carbachol. As expected, a time-dependent
carbachol-mediated phosphorylation of ERK1/2 was observed
(Fig. 8C). Interestingly, overnight incubation with pertussis toxin
diminished but not abolished the extent of the carbachol-mediated
ERK1/2 phosphorylation (Fig. 8C). This reduction indicates that Gαi/oy transfected with 3xHA-M3R, M4R or 3xHA-M5R. Serum-starved cells were overnight
treated with 10 µM carbachol (CCh) for 5 min. The phosphorylation of ERK1/2 was
f three independent experiments. (B) Quantiﬁcation of ERK1/2 phosphorylation. The
phospho-ERK1/2 protein were measured by densitometric scanning. All values of
in fold over the carbachol treated cells) of three independent experiments. *pb0.001.
Fig. 7. Effect of the M5R-3IL235–409 expression in the mAChRs-mediated ERK1/2 stimulation. (A) Cells were transiently transfected with 3xHA-M3R, M4R, 3xHA-M5R or 3xHA-M3R
plus 3xHA-M5R together in the absence (−) or the presence (+) the minigene (5 µg cDNA) encoding the control peptide Ops-3IL211–260 or the M5R-3IL235–409 peptide. Serum-
starved cells were treated with 10 µM carbachol (CCh) for 5 min. The phosphorylation of ERK1/2 was determined as described before. Images are representative of three
independent experiments. (B) Quantiﬁcation of ERK1/2 phosphorylation. The intensities of the immunoreactive bands on X-ray ﬁlm corresponding to ERK1/2 and phospho-ERK1/2
protein were measured by densitometric scanning. All values of phosphorylated ERK1/2 were normalized using ERK1/2 and expressed as means±S.E.M. (in fold over the carbachol
treated Ops-3IL211–260 transfected cells) of three independent experiments. *pb0.001.
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phosphorylation of ERK1/2 in these cells. Thus, these results might be
explained either if the M5R would promiscuously couple to Gαi/o or if
an endogenously Gαi/o coupled mAChR is expressed in Molt-3 cells.
Indeed, it has been described thatMolt-3 cells express theM4R, a Gαi/o
coupled mAChR [36], thus the carbachol-mediated ERK1/2 phosphor-
ylation sensible to pertussis toxin might be due to this receptor
subtype.
Subsequently, we wanted to determine the effect of the M5R-
3IL235–409 peptide in the function of endogenously expressed mAChRs
in non-neuronal cells. To this end, we monitored the extent of
carbachol-mediated ERK1/2 phosphorylation in Molt-3 cells expres-
sing the minigene encoding the third intracellular loop of M5R. Thus,
treatment of Molt-3 cells with carbachol (10 µM) leads to a signiﬁcant
increase in the extent of phosphorylation of ERK1/2 (Fig. 9A). This
carbachol-mediated ERK1/2 phosphorylation was abolished by pre-
incubation with PD 98059, a selective non-competitive inhibitor of
the MAPK pathway (Fig. 9A). Interestingly, carbachol stimulation of
Molt-3 cells transfected with minigene (5 µg of cDNA) encoding the
M5R-3IL235–409 peptide leads to a signiﬁcative decrement in the extent
of ERK1/2 phosphorylation (Fig. 9A). Interestingly, it has happened in
the HEK-293T cells, the coexpression of the Ops-3IL211–260 control
peptide did not have effect on the carbachol-mediated ERK1/2
phosphorylation in Molt-3 cells (Fig. 9A). Collectively, these results
indicate that the effect of M5R-3IL235–409 peptide on mAChR function
in Molt-3 cells might be M3R/M5R-speciﬁc.
IL-2 production, which is the ﬁrst in a series of lymphocytotrophic
hormones, has a pivotal role in the generation and regulation of immune
response. Previous reports described that the muscarinic agonist
oxotremorineM(Oxo-M) enhancedphytohemagglutinin (PHA)-induced
IL-2 production in T-cells [18,37]. PHA-induced IL-2 production was
enhancedwhencellswerepre-treated formore than1 hwithOxo-M, and
a 24 h Oxo-M pre-treatment doubled PHA-induced cytokine production.
Thus, we wonder whether the pre-treatment of Molt-3 cells with
carbachol (10 µM) for 0–24 h in the absence or presence of theminigene
(5 µg cDNA) encoding M5R-3IL235–409 alters the carbachol-enhanced
PHA-induced IL-2 production. Thus, pre-incubation of Molt-3 cell with
10 µM of carbachol for 24 h enhanced (82 IU/ml) the PHA-induced IL-2
production (Fig. 9B). Interestingly, under the same experimental
conditions the Molt-3 cell transfected with the minigene encoding theM5R-3IL235–409 peptide showed a two fold less enhancement of the
carbachol-mediated PHA-induced IL-2 production (38 IU/ml; ANOVA,
Pb0.01) (Fig. 9B). Overall, we can conclude that the M5R-3IL235–409
modulates the M5R function and this modulation might be apparently
independent of the G protein activation as this peptide did not affect the
receptor G protein-binding (Fig. 3B).
4. Discussion
Muscarinic acetylcholine receptors are able to form homo- and
hetero-oligomers, the existence of which has been demonstrated by a
wide variety of approaches, including pharmacological analysis of
ligand–receptor interactions, co-immunoprecipitation, or, more recent-
ly, by means of resonance energy transfer-based methods (FRET and
BRET) [6,11,13]. However, the existence of heterodimers composed by
M3 and M5 muscarinic receptor subtypes has not been reported yet,
despite the large amount of experimental evidence that supports the
active role of these receptors in the non-neuronal cholinergic system.
In the present study we provide for the ﬁrst time evidences for the
existence of receptor–receptor interaction between M3R and M5R in
both HEK-293T and Molt-3 cells. Our results from quantitative BRET
saturation analysis show that M3R and M5R can form homodimers in
intact HEK-293T cells. A close analysis of BRET parameters (e.g. BRET50
and BRETmax) supported the existence of constitutive M3 and M5
mAChR homodimers in living cells. Interestingly, these results are in
agreementwith previous pharmacological and BRET experiments that
demonstrated M1R, M2R and M3R oligomerization [13]. Also, by using
the same approach we demonstrated that co-expression of M3R and
M5R results in the formation of heterodimers, a ﬁnding that was also
conﬁrmed by co-immunoprecipitation experiments. Interestingly, the
BRET50 values calculated for homo- and heterodimers were quite
similar, thus suggesting thatM3R andM5R have similar avidity to form
homo- and heterodimers when co-expressed in the same cell. These
results support the notion that muscarinic acetylcholine receptors
might potentially exist in living cells as a combined population of
receptor homo- and heterodimers. Although previous reports have
demonstrated that receptor agonist binding either promotes or
stabilizes receptor oligomerization, in our hands we did not observe
any change in the BRET parameters after carbachol challenge. These
results are in agreement with those describing that M3R agonist-
Fig. 8.M3R/M5R expression in Molt-3 cells. (A) Immunoﬂuorescence localization of M3R and M5R in Molt-3 cells. Cells were processed for immunocytochemistry (see Materials and
methods) using a goat anti-M3R and a rabbit anti-M5R. The bound primary antibody was detected using donkey–anti-goat-Cy2 and donkey–anti-rabbit-Cy3. Superimposition of
images reveals receptor co-distribution in yellow (merge). Scale bar: 10 µm. (B) Co-immunoprecipitation of M3R from Molt-3 cells. Solubilized extracts from Molt-3 cells were
subjected to immunoprecipitation analysis using rabbit anti-ﬂag antibody (4 µg/ml) (lane 1), rabbit anti-M3R polyclonal antibody (4 µg/ml) (lane 2) and rabbit anti-M5R polyclonal
antibody (4 µg/ml) (lane 3). Extracts (Crude) and immunoprecipitates (IP) were analyzed by SDS-PAGE and immunoblotted using a rabbit anti-M3R polyclonal antibody (1/1000)
and horseradish-peroxidase (HRP)-conjugated goat anti-rabbit as a secondary antibody. The immunoreactive bands were visualized by chemiluminescence. These blots are
representative of four different experiments with similar qualitative results. * denotes the cross-reactive IgGs used in the IP. (C) Activation of ERK1/2 in Molt-3 cells. Serum-starved
Molt-3 cells were overnight preincubated with vehicle (−PTX) or with 100 ng/ml of pertussis toxin (+PTX) and then treated with 10 µM carbachol (CCh) for the indicated times.
The phosphorylation of ERK1/2 was determined by immunoblotting (see Materials and methods). Bottom: representative ERK assay; top: the intensities of the immunoreactive
bands on X-ray ﬁlm corresponding to ERK1/2 and phospho-ERK1/2 protein were measured by densitometric scanning. All values of phosphorylated ERK1/2 were normalized using
ERK1/2 and expressed as means±S.E.M. (in fold over the nontreated cells) of three independent experiments. **pb0.01 when compared to basal conditions.
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addition, carbachol treatment of HEK 293 cells expressing homolo-
gous or heterologous combinations of M1R, M2R, and M3R fusion
proteins revealed no signiﬁcant changes in the BRET signal [13]. Thus,
it seems that agonist challenge of mAChRs does not affect receptor
oligomerization. Collectively, our data suggest that both M3R and M5R
can oligomerize in living cells and that this phenomena might be
physiologically relevant in native systems.
Extensive work using peptide strategies [32,37–41] as well as by
means of mutagenesis and cross-linking experiments [32,37–41] had
identiﬁed structural determinants that can affect both GPCR oligo-merization and function. Thus, in an attempt to better understand the
structural determinants involved in the M3R–M5R protein–protein
interaction, we investigated the effects of the M5R third intracellular
loop on receptor oligomerization and function. Indeed, a peptide
derived from this receptor domain reduced the degree of M3R and
M5R heterodimerization as determined by BRET experiments. Also,
the same peptide abolished the carbachol-mediated ERK1/2 phos-
phorylation in HEK-293T cells coexpressing M3R and M5R. Thus, the
expression of the M5R-3IL235–409 peptide speciﬁcally targets the M3R/
M5R heteromeric function without affecting the singly M3R or M5R
function. Therefore, we show for the ﬁrst time a speciﬁc function
Fig. 9.Modulation of M3/M5 receptor signal transduction in Molt-3 cells. (A) Activation
of ERK1/2 in Molt-3 cells. Cells were transfected with the minigene (5 µg cDNA)
encoding the control peptide Ops-3IL211–260 or the M5R-3IL235–409 peptide and the
activation of ERK1/2 was determined after 5 min of carbachol (CCh) stimulation. Molt-
3 cells non-stimulated with carbachol (lane 1) and CCh-stimulated in presence of MAPK
speciﬁc inhibitor PD-98059 (lane 2) were performed as an internal control. The
phosphorylation of ERK1/2 was determined by immunoblotting (see Materials and
methods). Lower panels: representative ERK assay; upper panel: the intensities of the
immunoreactive bands on X-ray ﬁlm corresponding to ERK1/2 and phospho-ERK1/2
protein were measured by densitometric scanning. All values of phosphorylated ERK1/
2 were normalized using ERK1/2 and expressed as means±S.E.M. (in fold over the
nontreated cells) of three independent experiments. *pb0.05 and ***pb0.001.
(B) mAChR stimulation enhanced PHA-IL-2 production. Molt-3 cells were treated
with CCh (10 µM) for 0–24 h in the absence (■) or presence ( ) of the minigene (5 µg
cDNA) encoding M5R-3IL235–409 peptide and the carbachol-enhanced PHA-induced IL-2
production was determined as described in Materials and methods. Values are
expressed as IU (1 IU/ml=0.2 ng/ml) and expressed as means±S.E.M of four
independent experiments (ANOVA, pb0.01).
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mention that in the muscarinic receptor family, precisely in the M3
subtype, a functional role of the third intracellular loop in receptor
dimerization has been proposed [42]. Overall, these results support
the notion that in GPCR oligomerization different structural determi-
nants are involved and these might differ among receptors.
Interestingly, the expression of a M5R third intracellular loop peptide,
which had not affect on the receptor-mediated G protein-activation,
modiﬁes the distance and/or orientation (measured by a BRET
approach) between M3R and M5R within the heterodimer, thus
affecting the oligomerization state itself.
The physiological role for the most part of GPCR oligomers
described so far remains to be unraveled. For instance, the functional
consequences of muscarinic acetylcholine receptor oligomerization in
general and M3R/M5R heterodimerization in particular are still
unknown. It is intriguing why two receptors, M3R and M5R, which
have apparently similar functionality after acetylcholine activation doheteromerize, and therefore, which will be the physiological con-
sequences of this phenomena. Interestingly, these two receptor
subtypes coexpress in many acetylcholine-sensitive tissues like
striatal dopamine neurons [43], the gastrointestinal tract [44] and T
and B lymphocytes cells [15], suggesting that heterodimerization
could indeed occur in native mammalian tissues if simultaneous
expression of M3R and M5R take place in the same cell. As these two
receptor subtypes have similar pharmacological characteristics (e.g.
comparable afﬁnities for the same ligands) the classical radioligand
binding assays studies of the M3R/M5R oligomer is difﬁcult to achieve
in cells coexpressing both receptors (e.g. T-lymphocyte). Hence, if the
conditions made the pharmacological approach difﬁcult to accom-
plish then the knowledge of the structural determinants governing
the M3R/M5R heterodimer would help in part to understand the
potential role of receptor oligomerization in the acetylcholine-
mediated signal transduction. Subsequently, we tested the functional
consequences of a M5R third intracellular loop peptide expression in a
derived T-lymphocyte cell line which was shown to endogenously
express M3R and M5R. Interestingly, we choose the M5R-3IL235–409
peptide as did not have any effect on the receptor-mediated G
protein-activation but modiﬁed the M3R/M5R oligomerization state
and abolish the M3R/M5R-mediated ERK1/2 phosphorylation in HEK-
293T cells. Under these premises, when the muscarinic signal
transduction and cytokine production in lymphocytic T-cells were
tested the M5R-3IL235–409 peptide was shown to signiﬁcantly reduce
both the carbachol-mediated ERK1/2 phosphorylation and the
carbachol-enhanced PHA-induced IL-2 production in Molt-3 cells.
These results might lead to the contention that the functional effects
mediated by the M5R-3IL235–409 peptide, which on the other hand are
independent of the G protein activation, might be someway related to
direct protein–protein interactions that also will modulate M3R/M5R
oligomerization and which in turn will affect the cholinergic signaling
in lymphocytic T-cells. Indeed, more experimental work will be
needed to fully elucidate the role of mAChRs oligomerization in
lymphocytic cholinergic function. Overall, we can conclude that
mAChRs oligomerization might potentially provide the molecular
framework that support the diverse cholinergic signaling observed in
lymphocytic cells, a fact that must be considered during therapeutic
intervention of the immune system.
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